Replies to post #44122 on Curative Biotechnology Inc (CUBT)

[Student of the Game]

Remember that NIH through the CRADA will be paying MOST of the IND costs for the AMD trial (all except travel expenses). CUBT has to pay to provide the drug, but NIH will pay for the trial.

CUBT needs to raise enough money to qualify to be uplisted to the NYSE/Amex.